Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Healthcare Sector Analysis

UpdatedJan 12, 2026
DataAggregated Company Financials
Companies127
  • 7D2.4%
  • 3M0.2%
  • 1Y21.1%
  • YTD1.5%

The Healthcare industry has gained 2.4% in the last week and Bright Minds Biosciences up 18%. In the same time, ME Therapeutics Holdings was down 25%. This means that the industry has gained 21% over the past year. Looking forward, earnings are forecast to grow by 68% annually.

Sector Valuation and Performance

Has the Canadian Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 12 Jan 2026CA$36.3bCA$19.3b-CA$2,234,318,057.7222.7x-16.2x1.9x
Wed, 10 Dec 2025CA$33.1bCA$19.2b-CA$2,177,145,205.6720.6x-15.2x1.7x
Fri, 07 Nov 2025CA$33.9bCA$19.0b-CA$2,210,338,643.5726.1x-15.3x1.8x
Sun, 05 Oct 2025CA$38.1bCA$19.4b-CA$2,314,607,436.3142.5x-16.5x2x
Tue, 02 Sep 2025CA$36.3bCA$20.0b-CA$2,787,186,515.6944.9x-13x1.8x
Thu, 31 Jul 2025CA$29.0bCA$19.6b-CA$2,762,618,790.4520.1x-10.5x1.5x
Sat, 28 Jun 2025CA$27.2bCA$19.5b-CA$2,789,990,521.6120.8x-9.7x1.4x
Mon, 26 May 2025CA$40.8bCA$19.6b-CA$2,682,158,941.3020.8x-15.2x2.1x
Wed, 23 Apr 2025CA$24.7bCA$19.6b-CA$2,798,783,630.2425.7x-8.8x1.3x
Fri, 21 Mar 2025CA$26.6bCA$19.9b-CA$2,810,056,918.1720.9x-9.5x1.3x
Sun, 16 Feb 2025CA$28.6bCA$19.7b-CA$2,496,592,271.1127.4x-11.5x1.5x
Tue, 14 Jan 2025CA$28.1bCA$19.8b-CA$2,728,477,656.8729.4x-10.3x1.4x
Thu, 12 Dec 2024CA$29.6bCA$19.6b-CA$2,882,544,540.7124.1x-10.3x1.5x
Sat, 09 Nov 2024CA$31.1bCA$19.6b-CA$3,149,096,202.3417x-9.9x1.6x
Mon, 07 Oct 2024CA$32.7bCA$19.3b-CA$2,951,499,763.6221.3x-11.1x1.7x
Wed, 04 Sep 2024CA$31.2bCA$19.3b-CA$2,967,352,496.9621.4x-10.5x1.6x
Fri, 02 Aug 2024CA$34.0bCA$19.3b-CA$3,678,615,557.0219.9x-9.3x1.8x
Sun, 30 Jun 2024CA$32.7bCA$19.3b-CA$3,793,507,137.8120.6x-8.6x1.7x
Tue, 28 May 2024CA$34.0bCA$19.5b-CA$4,057,210,701.5917.7x-8.4x1.7x
Thu, 25 Apr 2024CA$34.8bCA$19.4b-CA$4,052,637,433.9213.7x-8.6x1.8x
Sat, 23 Mar 2024CA$36.4bCA$19.4b-CA$4,017,209,394.9613.7x-9.1x1.9x
Mon, 19 Feb 2024CA$34.1bCA$19.3b-CA$5,204,326,536.4415.4x-6.6x1.8x
Wed, 17 Jan 2024CA$37.1bCA$20.1b-CA$7,688,661,394.0010.2x-4.8x1.8x
Fri, 15 Dec 2023CA$32.6bCA$20.0b-CA$7,683,721,674.0013x-4.2x1.6x
Sun, 12 Nov 2023CA$32.1bCA$20.1b-CA$7,760,225,517.0017.2x-4.1x1.6x
Tue, 10 Oct 2023CA$33.5bCA$20.0b-CA$8,389,535,164.0016.9x-4x1.7x
Thu, 07 Sep 2023CA$35.6bCA$20.6b-CA$8,960,081,500.0017.3x-4x1.7x
Sat, 05 Aug 2023CA$30.8bCA$20.7b-CA$10,841,960,606.0020.4x-2.8x1.5x
Mon, 03 Jul 2023CA$30.4bCA$20.6b-CA$10,593,457,691.0021.7x-2.9x1.5x
Wed, 31 May 2023CA$30.6bCA$20.9b-CA$11,640,373,757.0016.5x-2.6x1.5x
Fri, 28 Apr 2023CA$31.8bCA$21.7b-CA$11,347,790,730.0015.6x-2.8x1.5x
Sun, 26 Mar 2023CA$31.3bCA$22.1b-CA$11,401,078,486.0016.6x-2.7x1.4x
Tue, 21 Feb 2023CA$36.1bCA$21.9b-CA$11,658,712,332.0019.6x-3.1x1.6x
Thu, 19 Jan 2023CA$36.1bCA$21.9b-CA$11,542,122,303.0019.5x-3.1x1.6x
Price to Earnings Ratio

-3.1x


Total Market Cap: CA$36.1bTotal Earnings: -CA$11,542,122,303.00Total Revenue: CA$21.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Healthcare Sector Price to Earnings3Y Average -8.3x202420252026
Current Industry PE
  • Investors are optimistic on the Canadian Healthcare industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 1.6x is lower than the industry's current PS ratio of 1.9x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 4.1% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare sector?

CA Market1.46%
Healthcare2.39%
Medical Equipment9.04%
Pharma3.97%
Life Sciences3.14%
Biotech2.00%
Healthcare Services0.93%
Healthtech-2.01%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio.
    • Analysts are expecting annual earnings growth of 83.2%, which is higher than its past year's earnings growth of 42.4% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 83% over the next 5 years.
  • This is better than its past earnings growth rate of 42% per year.
  • In contrast, the Biotech industry is expected to see its earnings grow by 2.1% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DRUG Bright Minds BiosciencesCA$122.7118.0%
+CA$145.7m		119.1%PB11.6x
TRUL Trulieve CannabisCA$12.097.0%
+CA$133.8m		64.3%PS1.2x
GTII Green Thumb IndustriesCA$11.265.3%
+CA$132.3m		7.8%PE43x
VREO Vireo GrowthCA$0.8514.9%
+CA$128.0m		10.4%PS3.5x
CURA Curaleaf HoldingsCA$3.502.3%
+CA$61.8m		70.7%PS1.5x

Latest News

TRUL
CA$12.09
Trulieve Cannabis
7D
7.0%
1Y
64.3%

TRUL: Retail Expansion And Rescheduling Progress Will Support Higher Future Earnings Multiples

Analysts have made a small upward adjustment to their Trulieve Cannabis fair value estimate, reflecting only modest tweaks to long term profit margin and future P/E assumptions rather than a wholesale shift in their outlook. Analyst Commentary Recent Street research around comparable business services and data providers offers some useful clues for how analysts may be thinking about Trulieve Cannabis valuation and execution, even though the coverage is focused on different companies.
CSH.UN
CA$20.23
Chartwell Retirement Residences
7D
-0.3%
1Y
36.7%

CSH.UN: New Buy Rating And Higher Price Objective Will Support Upside

Analysts have nudged their targets higher for Chartwell Retirement Residences, with recent C$22 and C$25 price objectives helping to underpin an updated fair value estimate of $22.95 that is supported by largely unchanged key model inputs. Analyst Commentary Recent research coverage has centered on higher price objectives and supportive ratings, which collectively align with the updated fair value estimate of $22.95.
HITI
CA$3.71
High Tide
7D
-2.9%
1Y
-15.9%
SIA
CA$21.02
Sienna Senior Living
7D
-0.4%
1Y
42.1%
WELL
CA$4.23
WELL Health Technologies
7D
3.9%
1Y
-36.1%

WELL: Future Margin Expansion And Sector Tailwinds Will Support Upside

Analysts trimmed their price target on WELL Health Technologies to C$5.50 from C$6.00, reflecting updated assumptions around profit margins and a lower future P/E. They maintained a Neutral stance on the shares.
CL
CA$1.76
Cresco Labs
7D
7.3%
1Y
33.3%

CL: German Entry And Higher Margins Will Support Future Upside

Analysts have raised their price target for Cresco Labs from US$2.30 to about US$2.36, reflecting updated views on the company’s profit margin outlook and a lower assumed future P/E multiple. What's in the News Cresco Labs launched Cresco branded flower in Germany, marking its first commercial entry into the European Union and extending its growth plans beyond the U.S. cannabis market (Key Developments).
DRUG
CA$122.71
Bright Minds Biosciences
7D
18.0%
1Y
119.1%
HBFG
CA$2.12
Happy Belly Food Group
7D
-4.5%
1Y
66.9%
CURA
CA$3.50
Curaleaf Holdings
7D
2.3%
1Y
70.7%

CURA: Regulatory Shifts Will Widen Moat And Support Destination Brand Position

Analysts have lifted their price target on Curaleaf Holdings to C$5.00 from C$4.81, pointing to regulatory momentum and what they see as a stronger product offering that could help the company reinforce its position with consumers. Analyst Commentary Recent commentary has focused on how regulatory shifts and Curaleaf's product positioning could influence the company’s valuation and execution over time.
PRN
CA$11.71
Profound Medical
7D
10.0%
1Y
9.5%
METX
CA$3.00
ME Therapeutics Holdings
7D
-25.0%
1Y
-21.1%
GTII
CA$11.26
Green Thumb Industries
7D
5.3%
1Y
7.8%

Here's Why Green Thumb Industries (CSE:GTII) Can Manage Its Debt Responsibly

Jan 06
Here's Why Green Thumb Industries (CSE:GTII) Can Manage Its Debt Responsibly
VREO
CA$0.85
Vireo Growth
7D
14.9%
1Y
10.4%
NURS
CA$4.60
Hydreight Technologies
7D
-7.3%
1Y
100.9%

Investors Still Aren't Entirely Convinced By Hydreight Technologies Inc.'s (CVE:NURS) Revenues Despite 25% Price Jump

Dec 31
Investors Still Aren't Entirely Convinced By Hydreight Technologies Inc.'s (CVE:NURS) Revenues Despite 25% Price Jump
ATLE
CA$0.17
Atlas Energy
7D
-10.8%
1Y
-52.9%
HBP
CA$2.26
Helix BioPharma
7D
-7.0%
1Y
151.1%